GlassScriptPhysician profile
Joe B Henry
NPI 1184810392
$6,785.85
in general payments reported to CMS, 2019-2025
30 companies · $845 in 2025
The $845 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $488 · 2021: $1,150 · 2022: $1,147 · 2023: $1,790 · 2024: $668 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,172.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $893.06 | 2020-2025 | |
| Amgen INC. | $831.26 | 2019-2023 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $827.94 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $637.39 | 2019-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $428.51 | 2019-2025 | Trintellix |
| Pfizer INC. | $407.64 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.91 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $123.59 | 2020-2023 | Ajovy |
| Biohaven Pharmaceuticals, INC. | $108.59 | 2020-2021 | |
| Abbott Laboratories | $101.69 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $85.56 | 2023-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $79.45 | 2023 | Quviviq |
| Exact Sciences Corporation | $77.43 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.28 | 2019-2023 | Xifaxan, Trulance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $67.17 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $63.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.51 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $56.92 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $54.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $54.61 | 2022 | |
| Glaxosmithkline, LLC. | $53.95 | 2021-2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $51.25 | 2023 | Seglentis, Livalo |
| Antares Pharma, INC. | $39.71 | 2020 | |
| Corcept Therapeutics | $38.90 | 2023 | Korlym |
| Genentech USA, INC. | $38.86 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $37.30 | 2020-2023 | Linzess |
| Sanofi-Aventis U.S. LLC | $35.46 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.73 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $22.58 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.